To address this issue, short‐term intensive insulin therapy (SIIT) has historically been used in patients with type 2 diabetes mellitus (T2DM) experiencing severe hyperglycemia [2, 3, 4, 5]. The gene discussed is INS; the disease is Hyperglycemia.